中国临床药理学与治疗学2018，Vol.23Issue(1)：65-72,8.DOI:10.12092/j.issn.1009-2501.2018.01.013
特力利汀治疗2型糖尿病长期效果的Markov模型
Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus
摘要
Abstract
AIM:To investigate the long-term efficacy and safety of teneligliptin as dipeptidyl-peptidase Ⅳ (DPP-4) inhibitor for type 2 diabetes mellitus and estimate the long-term efficacy.METHODS:Search the literature in databases of PubMed,The Cochrane Library,Embase,CNKI,Wan Fang,CQVIP and so on.Randomized controlled trials (RCT) of teneligliptin for the treatment of T2DM were collected with time limit from establishment to June,2017.References and related professional magazine were also retrieved manually.Two researchers independently screened these literatures according to the inclusion and exclusion criteria,extracted basic information and assessed the methodological quality of included studies.Meta-analysis of the indexes was performed by using RevMan 5.3.Evaluate the long-term efficacy by establishing a new Markov model.RESULTS:Five RCTs were collected,including 903 diabetic patients.The results of meta-analysis showed teneligliptin can effectively reduce the main index HbA1c [SMD =-0.87,95％ CI(-0.99,-0.76),P ＜ 0.000 01] and FPG [SMD=-0.71,95％CI (-0.85,-0.58),P＜0.000 01],increase the secondary index HOMA-β [SMD =0.46,95％ CI (0.33,0.60),P ＜0.000 01] than placebo group.And there was significant difference between them (P ＜ 0.05).And Markov model showed teneligliptin can decrease the numbers of death.CONCLUSION:As the new kind of hypoglycemic agent,dipeptidyl peptidase-Ⅳ (DPP-4) inhibitor teneligliptin can reduce the blood glucose effectively with no increased risk of hypoglycemia,protect the β-cell function of type 2 diabetic mellitus and decrease the rate of diabetes complications and death.关键词
二肽基肽酶Ⅳ抑制剂/特力利汀/2型糖尿病/系统评价/Markov模型Key words
dipeptidyl peptidase-Ⅳ inhibitor/teneligliptin/type 2 diabetes mellitus/systematic review/Markov model分类
医药卫生引用本文复制引用
张春燕,范小冬,秦元,孔文强,周春阳,杜彪..特力利汀治疗2型糖尿病长期效果的Markov模型[J].中国临床药理学与治疗学,2018,23(1):65-72,8.基金项目
重庆市社会事业与民生保障科技创新专项(cstc2015shmszx120073)(cstc2017shmsA130105) （cstc2015shmszx120073）
重庆市万州区科技计划基金资助项目(201403055) （201403055）
